-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $50

Benzinga·03/03/2026 14:44:59
Listen to the news
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $45 to $50.